Clinical Trial Update: Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) [Phase 2]

View source ↗

Summary

Phase 2 trial of pazopanib in patients with imatinib-refractory or intolerant gastrointestinal stromal tumors; the study was terminated and results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: Kristen Ganjoo | Conditions: Gastrointestinal Stromal Tumor (GIST) | Phase 2 | Status: TERMINATED | Results posted: 2017-04-07